Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | RNF4 | P78317 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1260162 | 1.00 | ALDH1A1 (0.48) | ALDH1A1LMNARNF4NR3C1SMN1; SMN2 | |
| SCHEMBL1258225 | 0.85 | ALDH1A1 (0.40) | ALDH1A1LMNASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL1258227 | 0.85 | ALDH1A1 (0.40) | ALDH1A1LMNASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL1259107 | 0.85 | KDM4E (0.39) | ALDH1A1LMNANR3C1SMN1; SMN2KDM4E | |
| SCHEMBL1259102 | 0.85 | KDM4E (0.39) | ALDH1A1LMNANR3C1SMN1; SMN2KDM4E | |
| SCHEMBL1260519 | 0.81 | RNF4 (0.51) | RNF4NR3C1SMN1; SMN2PTGESGAA | |
| SCHEMBL29806360 | 0.79 | PIN1 (0.47) | ALDH1A1LMNAKDM4ETSHRRAB9A | |
| SCHEMBL2659166 | 0.79 | PIN1 (0.47) | ALDH1A1LMNAKDM4ETSHRRAB9A | |
| SCHEMBL4551195 | 0.79 | SMN1; SMN2 (0.41) | ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL12892581 | 0.74 | MAPT (0.54) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| WO-2009136663-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | ABL1, MAP4K2, MAP3K20 | ALDH1A1 2255/4885LMNA 3734/4885RNF4 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.